We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Arch Biopartners Inc (ARCH) NPV

Sell:1.94 CAD Buy:1.95 CAD Change: No change
Market closed |  Prices as at close on 5 December 2024 | Switch to live prices |
Sell:1.94 CAD
Buy:1.95 CAD
Change: No change
Market closed |  Prices as at close on 5 December 2024 | Switch to live prices |
Sell:1.94 CAD
Buy:1.95 CAD
Change: No change
Market closed |  Prices as at close on 5 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

Contact details

Address:
545 King St W.
TORONTO
M5X 1A1
Canada
Telephone:
+1 (647) 4287031
Website:
https://archbiopartners.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ARCH
ISIN:
CA03938C1041
Market cap:
127.34 million CAD
Shares in issue:
64.86 million
Sector:
Life Sciences Tools & Services
Exchange:
Canadian Venture Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Richard Muruve
    President, Chief Executive Officer, Director
  • Andrew Bishop
    Chief Financial Officer, Director
  • Daniel Muruve
    Chief Science Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.